title: [Pulmonary neuroendocrine neoplasms].
abstract: The pulmonary neuroendocrine neoplasms originate from the enterochromaffin cells which are diffusely distributed in the body. The incidence of these tumors has increased significantly in recent decades due to the available diagnostics. They make up about 1-2% of all lung tumors and 20-30% of all neuroendocrine neoplasms. The current WHO classification from 2004 divides them into typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC) and small cell carcinomas (SCLC). The major neuroendocrine biomarkers are chromogranin A, synaptophysin and CD56. TC have a low mitotic rate of <2 mitoses/2mm(2) (10 HPF), whereas the mitotic rate of the AC is 2-10 mitoses/2 mm(2) (10 HPF). The Ki-67 staining is helpful to distinguish typical and atypical carcinoids from the highly malignant LCNEC and SCLC. Clinically, the patient presents usually with cough, hemoptysis or bronchial obstruction. The occurrence of a carcinoid or Cushing's syndrome and a tumor-associated acromegaly are rare. Surgical resection with radical lymph node dissection is the treatment of choice for achieving long-term survival. Endoscopic resection of the endobronchial tumor growth is a good alternative for inoperable endobronchially localized tumors. Peptide receptor radionuclide therapy (PRRT) is a promising treatment option for patients with metastatic or unresectable pulmonary neuroendocrine tumors. New targeted therapies using angiogenesis inhibitors, mTOR inhibitors, and tyrosine kinase inhibitors are being tested for their effectiveness in many previous studies. Typical carcinoid tumors metastasize less frequently than AC, the 5-year survival rate of patients with TC being over 90%. Patients with AC have a 5-year survival rate between 35% and 87%. The highly malignant LCNEC and SCLC, on the other hand, have a 5-year survival rate between 15% and 57%, and <5% respectively. The increasing number of therapeutic options and diagnostic procedures requires a multidisciplinary approach and decision-making in multidisciplinary tumor conferences to ensure a personalized treatment approach. Therefore patients with a neuroendocrine neoplasm of the lung should be treated in specialized centers.
authors.affiliation: Klinik für Pneumologie der Zentralklinik Bad Berka GmbH.
authors.forename: Y
authors.initials: Y
authors.lastname: Sayeg
authors.affiliation: Zentrum für Neuroendokrine Tumore Bad Berka - ENETS Center of Excellence und Klinik für Innere Medizin, Gastroenterologie und Endokrinologie.
authors.forename: M
authors.initials: M
authors.lastname: Sayeg
authors.affiliation: Klinik für Molekulare Radiotherapie, Zentrum für Molekulare Bildgebung (PET/CT).
authors.forename: R P
authors.initials: RP
authors.lastname: Baum
authors.affiliation: Klinik für Molekulare Radiotherapie, Zentrum für Molekulare Bildgebung (PET/CT).
authors.forename: H R
authors.initials: HR
authors.lastname: Kulkarni
authors.affiliation: Klinik für Thorax- und Gefäßchirurgie der Zentralklinik Bad Berka GmbH.
authors.forename: N
authors.initials: N
authors.lastname: Presselt
authors.affiliation: Klinik für Pneumologie der Zentralklinik Bad Berka GmbH.
authors.forename: I
authors.initials: I
authors.lastname: Mäder
authors.affiliation: Institut für Pathologie in Bad Berka.
authors.forename: A
authors.initials: A
authors.lastname: Kunze
authors.affiliation: Institut für Pathologie in Bad Berka.
authors.forename: J
authors.initials: J
authors.lastname: Sänger
authors.affiliation: Zentrum für Neuroendokrine Tumore Bad Berka - ENETS Center of Excellence und Klinik für Innere Medizin, Gastroenterologie und Endokrinologie.
authors.forename: D
authors.initials: D
authors.lastname: Hörsch
authors.affiliation: Klinik für Pneumologie der Zentralklinik Bad Berka GmbH.
authors.forename: R
authors.initials: R
authors.lastname: Bonnet
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D004724:Endoscopy / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D015995:Prevalence; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor